10/540,519

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

 NEWS 1   Web Page for STN Seminar Schedule - N. America
 NEWS 2 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches
                  Zentralblatt
 NEWS 3 OCT 19 BEILSTEIN updated with new compounds
 NEWS 4 NOV 15 Derwent Indian patent publication number format enhanced
 NEWS 5 NOV 19 WPIX enhanced with XML display format
 NEWS 6 NOV 30 ICSD reloaded with enhancements
 NEWS 7 DEC 04 LINPADOCDB now available on STN
 NEWS 8 DEC 14 BEILSTEIN pricing structure to change
 NEWS 9 DEC 17 USPATOLD added to additional database clusters
 NEWS 10 DEC 17 IMSDRUGCONF removed from database clusters and STN
 NEWS 11 DEC 17 DGENE now includes more than 10 million sequences
 NEWS 12 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in
                  MEDLINE segment
 NEWS 13 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
 NEWS 14 DEC 17 CA/CAplus enhanced with new custom IPC display formats
 NEWS 15 DEC 17 STN Viewer enhanced with full-text patent content
                  from USPATOLD
 NEWS 16 JAN 02 STN pricing information for 2008 now available
 NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS 19 JAN 28 MARPAT searching enhanced
 NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 22 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 23 FEB 08 STN Express, Version 8.3, now available
 NEWS 24 FEB 20 PCI now available as a replacement to DPCI
 NEWS 25 FEB 25 IFIREF reloaded with enhancements
 NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements
 NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification

 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS   STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN   Welcome Banner and News Items
 NEWS IPC8   For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:48:48 ON 27 MAR 2008

=> file reg

McIntosh

```
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.42       0.42

FILE 'REGISTRY' ENTERED AT 15:49:39 ON 27 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 MAR 2008  HIGHEST RN 1010293-80-7
DICTIONARY FILE UPDATES:  26 MAR 2008  HIGHEST RN 1010293-80-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540519.str

L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 15:50:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       25 TO ITERATE

100.0% PROCESSED       25 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          200 TO      800
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> d l2

L2   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   721959-65-5  REGISTRY
ED   Entered STN:  04 Aug 2004
CN   β-D-Glucopyranoside, 3-[(3-fluoro-4-methylphenyl)methyl]-4,6-dimethyl-
     2-pyridinyl (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C21 H26 F N O6
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 sss full
FULL SEARCH INITIATED 15:50:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 593 TO ITERATE

100.0% PROCESSED 593 ITERATIONS 38 ANSWERS
SEARCH TIME: 00.00.01

L3 38 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.82	181.24

FILE 'CAPLUS' ENTERED AT 15:50:49 ON 27 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Mar 2008 VOL 148 ISS 13
FILE LAST UPDATED: 26 Mar 2008 (20080326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d bib abs hitstr 1-3 l4

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:996200 CAPLUS
DN 141:424380
TI Preparation of pyrimidine monosaccharides as sodium-dependent glucose
transporters and antidiabetic agents

IN Zenkoh, Tatsuya; Eikyu, Yoshiteru; Furukawa, Takako; Kodama, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004099230	A1	20041118	WO 2004-JP6357	20040430

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI AU 2003-902263 A 20030512
OS MARPAT 141:424380
GI



I

AB Pyrimidine monosaccharides I, wherein R1 = H, lower alkyl; R2 = H, lower alkoxy; R3 = H, OH; R4 = H, lower alkoxycarbonyl, hydroxymethyl; and the delocalized bond represents single bond or double bond, or a pharmaceutically acceptable salt thereof, were prepared Pyrimidine monosaccharides I and a salt thereof of the present invention are SGLTs, especially SGLT II selective, inhibitors and are useful for the prevention and/or treatment of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, wound healing, insulin resistance, hyperglycemia, hyper-insulinemia, Syndrome X, diabetic complications, or elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, atherosclerosis, hypertension, or for increasing high d. lipoprotein levels and the like, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of title compds.. Thus, (2S,3R,4S,5R,6R)-2-[[5-(4-ethyl-benzyl)-2-methoxy-4-pyrimidinyl]oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol was prepared and tested for human SGLT I (IC50 > 100 μM) and SGLT II (IC50 = 0.82 μM) inhibiting activities. In general, amts. between 0.01 mg/body and about 1,000 mg/kg may be administered per day.
IT 794521-34-9P 794521-35-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine monosaccharides as sodium-dependent glucose transporters and antidiabetic agents)
RN 794521-34-9 CAPLUS
CN β-D-Glucopyranoside, 5-[(4-ethylphenyl)methyl]-2-methoxy-4-pyrimidinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 794521-35-0 CAPLUS
CN β-D-Galactopyranoside, 5-[(4-ethylphenyl)methyl]-2-methoxy-4-pyrimidinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 794521-29-2P 794521-30-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine monosaccharides as sodium-dependent glucose transporters and antidiabetic agents)

RN 794521-29-2 CAPLUS
CN β-D-Glucopyranoside, 5-[(4-ethylphenyl)methyl]-2-methoxy-4-pyrimidinyl, 2,3,4,6-tetrabenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 794521-30-5 CAPLUS
CN β-D-Galactopyranoside, 5-[(4-ethylphenyl)methyl]-2-methoxy-4-pyrimidinyl, 2,3,4,6-tetrabenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:566633 CAPLUS
DN 141:123854
TI Preparation of D-glucose derivatives as human SGLT2 inhibitors
IN Fujikura, Hideki; Nishimura, Toshihiro; Katsuno, Kenji; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058790	A1	20040715	WO 2003-JP16310	20031219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2509835	A1	20040715	CA 2003-2509835	20031219
	AU 2003289440	A1	20040722	AU 2003-289440	20031219
	EP 1577317	A1	20050921	EP 2003-780923	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006035840	A1	20060216	US 2005-540519	20050623
PRAI	JP 2002-374016	A	20021225		
	WO 2003-JP16310	W	20031219		

OS MARPAT 141:123854
GI



I



II

AB The title compds. I [wherein X1-X4 = independently N, (un)substituted CH, etc.; R ≠ 4-Z-Ph; Z = H, halo, (un)substituted alkyl, alkoxy, etc.]

or pharmaceutically acceptable salts or prodrugs thereof are prepared as human SGLT2 activity inhibitors. For example, the compound II was prepared in a four-step synthesis. II inhibited human SGLT2 with IC50 of 3 nM. I are useful as a preventive or a remedy for diseases caused by hyperglycemia such as diabetes, diabetic complications, and obesity (no data).

IT 721959-65-5P 721959-66-6P 721959-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of D-glucose derivs. as human SGLT2 inhibitors)

RN 721959-65-5 CAPLUS
CN β-D-Glucopyranoside, 3-[(3-fluoro-4-methylphenyl)methyl]-4,6-dimethyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 721959-66-6 CAPLUS
CN β-D-Glucopyranoside, 3-[(3-methylphenyl)methyl]-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 721959-67-7 CAPLUS
CN β-D-Glucopyranoside, 3-[(2-methylphenyl)methyl]-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 721959-70-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of D-glucose derivs. as human SGLT2 inhibitors)
RN 721959-70-2 CAPLUS
CN β-D-Glucopyranoside, 3-[(3-fluoro-4-methylphenyl)methyl]-4,6-dimethyl-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:5979 CAPLUS
DN 138:49945
TI Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
IN Nishimura, Toshihiro; Fujikura, Hideki; Fushimi, Nobuhiko; Tatani, Kazuya; Katsuno, Kenji; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000712	A1	20030103	WO 2002-JP6000	20020617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2455300	A1	20030103	CA 2002-2455300	20020617
AU 2002313248	A1	20030108	AU 2002-313248	20020617
EP 1405859	A1	20040407	EP 2002-738729	20020617

these compounds are excluded via a proviso in my app- tcm

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN	1537114	A	20041013	CN 2002-814975	20020617
BR	2002010510	A	20050111	BR 2002-10510	20020617
US	2005049203	A1	20050303	US 2004-481013	20040820
US	7271153	B2	20070918		
PRAI JP	2001-187368	A	20010620		
WO	2002-JP6000	W	20020617		

OS MARPAT 138:49945

GI



I

AB A nitrogenous heterocyclic derivative represented by the general formula (I), a pharmacol. acceptable salt thereof, or a prodrug of either. These have excellent human SGLT2 inhibitory activity and are useful as a preventive or remedy for diseases attributable to hyperglycemia such as diabetes. In the general formula [I; X1 and X3 each is nitrogen or CH; X2 is nitrogen or CR2; X4 is nitrogen or CR3 (provided that one or two of X1 to X4 are nitrogen); and R1, R2, and R3 are hydrogen, etc.].

IT 479481-37-3P, 2-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-3-[4-(2-Methoxymethyloxyethyl)benzyl]-4,6-dimethylpyridine 479481-38-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nitrogenous heterocyclic derivs. as antidiabetics and for other medicinal uses)

RN 479481-37-3 CAPLUS

CN β-D-Glucopyranoside, 3-[[4-[2-(methoxymethoxy)ethyl]phenyl]methyl]-4,6-dimethyl-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-38-4 CAPLUS

CN β-D-Glucopyranoside, 3-[[4-[2-(methoxymethoxy)ethyl]phenyl]methyl]-4,6-dimethyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 479481-29-3P, 6-(N-Acetylamino)-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-3-(4-ethylbenzyl)pyridine 479481-31-7P, 6-Amino-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-3-(4-ethylbenzyl)pyridine 479481-33-9P 479481-35-1P, 2-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-3-(4-methoxybenzyl)-4,6-dimethylpyridine 479481-41-9P 479481-43-1P 479481-45-3P 479481-46-4P, 4-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-5-(4-methoxybenzyl)-2,6-dimethylpyridine 479481-48-6P 479481-50-0P, 4-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-5-(4-Ethylbenzyl)-2,6-dimethylpyrimidine 479481-52-2P, 4-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-3-(4-butylbenzyl)-2,6-dimethylpyridine 479481-54-4P 479481-56-6P, 3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)-4-benzylpyridazine 479481-57-7P 479481-58-8P 479481-59-9P 479481-60-2P 479481-61-3P, 2-(β-D-Glucopyranosyloxy)-3-[4-(2-hydroxyethyl)benzyl)-4,6-dimethylpyridine 479481-62-4P 479481-63-5P, 4-(4-Ethoxybenzyl)-3-(β-D-Glucopyranosyloxy)pyridine 479481-64-6P, 2-(β-D-Glucopyranosyloxy)-3-(4-methoxybenzyl)pyridine 479481-65-7P, 4-(β-D-Glucopyranosyloxy)-5-(4-methoxybenzyl)-2,6-dimethylpyrimidine 479481-66-8P, 3-(β-D-Glucopyranosyloxy)-4-[4-(2-hydroxyethyl)benzyl)pyridine 479481-67-9P, 5-(4-Ethylbenzyl)-4-(β-D-Glucopyranosyloxy)-2,6-dimethylpyrimidine 479481-68-0P , 3-(4-Butylbenzyl)-4-(β-D-Glucopyranosyloxy)-2,6-dimethylpyridine 479481-69-1P 479481-70-4P 479481-71-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogenous heterocyclic derivs. as antidiabetics and for other medicinal uses)

RN 479481-29-3 CAPLUS
CN Acetamide, N-[5-[(4-ethylphenyl)methyl]-6-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-31-7 CAPLUS
CN β-D-Glucopyranoside, 6-amino-3-[(4-ethylphenyl)methyl]-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-33-9 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-4,6-dimethyl-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-35-1 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-4,6-dimethyl-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-41-9 CAPLUS
CN β-D-Glucopyranoside, 6-methoxy-3-[(4-methoxyphenyl)methyl]-4-methyl-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-43-1 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-ethoxyphenyl)methyl]-3-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-45-3 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-2-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-46-4 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-2,6-dimethyl-4-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-48-6 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-[2-(benzoyloxy)ethyl]phenyl]methyl]-3-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-50-0 CAPLUS
CN β-D-Glucopyranoside, 5-[(4-ethylphenyl)methyl]-2,6-dimethyl-4-pyrimidinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-52-2 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-butylphenyl)methyl]-2,6-dimethyl-4-pyridinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-54-4 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]pyrazinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-56-6 CAPLUS
CN β-D-Glucopyranoside, 4-(phenylmethyl)-3-pyridazinyl, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-57-7 CAPLUS
CN Acetamide, N-[5-[(4-ethylphenyl)methyl]-6-(β-D-glucopyranosyloxy)-2-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-58-8 CAPLUS
CN β-D-Glucopyranoside, 6-amino-3-[(4-ethylphenyl)methyl]-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-59-9 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-ethylphenyl)methyl]-4,6-dimethyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-60-2 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-4,6-dimethyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-61-3 CAPLUS
CN β-D-Glucopyranoside, 3-[[4-(2-hydroxyethyl)phenyl]methyl]-4,6-dimethyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-62-4 CAPLUS
CN β-D-Glucopyranoside, 6-methoxy-3-[(4-methoxyphenyl)methyl]-4-methyl-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-63-5 CAPLUS
CN β-D-Glucopyranoside, 4-[(4-ethoxyphenyl)methyl]-3-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-64-6 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-2-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-65-7 CAPLUS
CN β-D-Glucopyranoside, 5-[(4-methoxyphenyl)methyl]-2,6-dimethyl-4-pyrimidinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-66-8 CAPLUS
CN β-D-Glucopyranoside, 4-[[4-(2-hydroxyethyl)phenyl]methyl]-3-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-67-9 CAPLUS
CN β-D-Glucopyranoside, 5-[(4-ethylphenyl)methyl]-2,6-dimethyl-4-pyrimidinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-68-0 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-butylphenyl)methyl]-2,6-dimethyl-4-pyridinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-69-1 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]pyrazinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-70-4 CAPLUS
CN β-D-Glucopyranoside, 4-(phenylmethyl)-3-pyridazinyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 479481-71-5 CAPLUS
CN β-D-Glucopyranoside, 3-[(4-methoxyphenyl)methyl]-4,6-dimethyl-2-pyridinyl, 6-(methyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:48:48 ON 27 MAR 2008)

FILE 'REGISTRY' ENTERED AT 15:49:39 ON 27 MAR 2008
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 38 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:50:49 ON 27 MAR 2008
L4 3 S L3